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Abstract 
Generic drugs have been approved for use by the Food and Drug Administration 
(FDA) since 1984 on the basis of demonstrated bioequivalence as compared to the brand 
name version. Generic drugs constitute approximately two- thirds of all prescriptions 
dispensed in the US and account for <20% of total pharmaceutical expenditure (Patel et 
al., 2011). However, concerns about the safety and bioequivalence of the generic versions 
of specific drugs are raised regularly (Kesselheim et al., 2010). Despite evidence 
supporting bioequivalence, many observational studies have shown an increase in seizure 





2008; for review see Yamada & Welty, 2010). These issues have not slowed the 
trend by medical insurance companies to mandate use of generic drugs over brand name 
drugs, and commercial and government insurance programs continue to prioritize the use 
of generics in most circumstances (Keenum et al., 2012). Although the use of generic 
medications can result in substantial savings for the American patient, anecdotal evidence 
indicates that beliefs concerning the safety and effectiveness of generic drugs compared 
to brand name medication may persist among patient subgroups as well as among 
medical practitioners (Figueiras et al., 2010; Ngo et al., 2013). While generic drug 
substitution may lead to immediate cost savings, these substitutions may be associated 
with additional expenses incurred due to increased adverse events, lack of adherence to 
therapy, and to the resulting failure of those therapies (Shin et al. 2014).   
The purpose of this study is to examine: 1) the extent to which generic switch is 
practiced for privately insured US patients; 2) variations in adherence to AED 
medications for patients by brand name and generic AED and switching between the two, 
and 3) medical outcomes based on compliance to treatment. We examine factors 
associated with the use the antiepileptic brand drug Dilantin® manufactured by Pfizer, 
generic Phenytoin, and generic switch in 19-64 year old patients who have private 
insurance.  
 





Chapter 1: Introduction 
Background and Need for the Study 
Generic drugs have been approved for use by the Food and Drug Administration 
(FDA) since 1984 on the basis of demonstrated bioequivalence as compared to the brand 
name version. Generic drugs constitute approximately two- thirds of all prescriptions 
dispensed in the US and account for <20% of total pharmaceutical expenditure (Patel et 
al., 2011). Numerous studies (Andrade, 2015a; Andrade, 2015b; Davis et al., 2015; Jiang 
et al., 2015; Krauss et al., 2011) as well as general clinical acceptance and experience 
have validated this standard. However, concerns about the safety and bioequivalence of 
the generic versions of specific drugs are raised regularly (Kesselheim et al., 2010). 
Despite evidence supporting bioequivalence, many observational studies have shown an 
increase in seizure occurrence with the use of generic drug formulations in the treatment 
of epilepsy (Papsdorf et al., 2009; Berg et al., 2008; for review see Yamada & Welty, 
2010). Yet the issues raised about the current bioequivalence standards have not slowed 
the trend by medical insurance companies to mandate use of generic drugs over brand 
name drugs in order to realize cost savings. Commercial and government insurance 
programs have prioritized the use of generics in most circumstances (Keenum et al., 
2012).  Additionally, the use of generic medications can result in substantial savings for 





However, anecdotal evidence indicates that beliefs concerning the safety and 
effectiveness of generic drugs compared to brand name medication may persist among 
patient subgroups as well as among medical practitioners (Figueiras et al., 2010; Ngo et 
al., 2013). Studies have investigated patients’ perceptions of generics, and researchers 
report that although the consumer appreciates the cost savings from generics, some 
individuals are unwilling to use them, and medication compliance could be negatively 
affected (Kohli & Bueller, 2013, Shin et al., 2014).   
In a 2009 study of commercially insured adults (Kohli & Bueller, 2013), 94% of 
patients agreed that generics are less expensive than brand name, yet only 37.6% of 
respondents would rather take a generic than a brand name medication.  In the same 
study, researchers identified very different levels of acceptance of generic medications by 
individuals based on income and age (Kohli & Bueller, 2013). High-income patients were 
more likely than low-income patients to prefer generic medications. Older patients and 
more severely ill patients were more likely to report concerns about the safety of generics 
than healthy, high-income patients (Kohli & Bueller, 2013). Thus, while generic drug 
substitution may lead to immediate cost savings, it is possible that generic substitutions 
may be associated with additional expenses incurred due to increased adverse events, 
lack of adherence to therapy, and to the resulting failure of those therapies (Shin et al. 
2014). This effect may be especially pronounced in subgroups of patients characterized 
by factors such as culture, social status, or personal and psychological characteristics. 
Indeed, studies continue to show that disadvantaged consumers may be reluctant to use 





This distrust of generic substitutes may be especially dangerous for drugs that are 
essential for patient health and functioning. One example is the concern raised over 
generic substitution of drugs used for the management of epilepsy (Krauss et al., 2011; 
Kesselheim et al., 2010). The management of epilepsy requires anti-epileptic drugs 
(AEDs) in approximately 70-80% of patients, and some clinicians have raised concern 
that these patients may be at higher risk of non-adherence and seizures when switched 
from a brand name drug to generic AEDs (Kesselheim et al., 2010). This issue has raised 
such heated debate in the medical community that the FDA was requested by leading 
epilepsy organizations to issue a statement opposing mandatory switching from brand 
name drugs to generic AEDs. The FDA refused to issue a guidance statement on the 
matter, resulting in certain states (e.g. Hawaii, Tennessee) passing their own AED 
specific legislation. In these states, informed consent from both the provider and the 
patient is required before a generic substitution is permitted (Kesselheim et al., 2010). 
However, little is known about the current practice of switching from brand name to 
generic switch for AED. Table 1 outlines several organizations across the globe which 
have made legislation or strong recommendations regarding the use of generics in the 
treatment of epilepsy.  
Table 1 
Guidelines for generic prescription of AEDs (Atif et al., 2016) 
Country Organization Principal recommendations 
United 
States 
AAN The AAN argues the generic substitution of AEDs and advises to seek consent of attending physician 
Epilepsy Foundation Both physician and patient should give consent and to be notified upon substitution of AEDs 





Country Organization Principal recommendations 
product (either generic or brand) may be expected to 
have equivalent clinical effects 
American Epilepsy 
Society 
The physicians involved in epilepsy treatment are 
trained for selection of appropriate AEDs and their 
dosages to minimize or eradicate seizures and to avoid 
adverse events 
It is done by utilizing the best available scientific 
evidences and clinical expertise 
Also, the society contradicts the formulation 
substitution of AEDs without obtaining approval from 
the physician as well as the patient 
England NICE 
Be precautious while generic substitution of AEDs 
having complex pharmacokinetics that may cause 
larger differences in therapeutic effects upon minor 
changes in drug absorption 
Germany German chapter of ILAE 
A switch must be avoided for patients having well-
controlled seizures 
Consider a generic switch towards a lower cost AED 
only for the patients having poorly controlled seizures. 
It is better to initiate the treatment with a low-cost 
AED 
The serum drug levels should be monitored closely 
while switching and the patient should be informed 
about the potential risks 
Italy Italian chapter of ILAE 
For patients exhibiting partial controlled seizures upon 
treatment with a brand AED, it might be appropriate to 
switch to a generic product 
The patient should be informed about the properties 
and nature of these products 
A switch is not recommended for the patients having 
well-controlled seizures 
France LFCE 
AEDs belong to a class that may cause problems when 
substituted. It is recommended to avoid generic 
substitution of AEDs 
Poland Polish Society of Epileptology 
Because of an increased risk of deterioration in 





Country Organization Principal recommendations 
contraindicated 
Pharmacists should not make substitution without 
informing the physicians and the physicians are 
responsible to make aware the patients of all the 





Generic substitution of AEDs should not be made as 
different available formulations of AEDs are not 
switchable 
Sweden Swedish Medicinal Products Agency 
Switching between formulations may cause a poor 
control of seizures 
Netherland Netherlands Society of Child Neurology The substitution of AEDs is not recommended 
AAN American Academy of Neurology, FDA Food and Drug Administration, NICE 
National Institute for Health and Care Excellence, ILAE International League Against 
Epilepsy, LFCE Ligue Francaise Contre L’Epilepsie 
 
Background on Epilepsy 
Epilepsy is a heterogeneous, chronic and serious brain disorder with multiple 
manifestations. An epileptic seizure results from transient abnormal synchronization of 
neurons in the brain which disrupts normal patterns of neuronal communication, resulting 
in waxing and waning electrical discharges (Moshe et al., 2015). Epilepsy comprises 
many seizure types and epilepsy syndromes, some of which are life threatening (Schmidt 
& Schachter, 2014), and is defined as two or more unprovoked seizures. By this 
definition, epilepsy affects 45 million people worldwide and the incidence is 
approximately 26 to 40 per 100,000 person years (French & Pedley, 2008). The annual 
economic cost of epilepsy in the US in 2011 was $15.5 billion in direct healthcare 
associated costs as well as indirect costs due to employment loss, wage loss or reduction, 





empirically based on trial and error, and does not prevent or reverse the pathological 
process of the disorder (Schmidt & Schachter, 2014). 
Epilepsy is one of many chronic diseases in which medication non-adherence is 
problematic. Studies estimate that between 30% and 60% of patients with epilepsy are 
non-adherent to their drug regimen, which can lead to higher seizure recurrence and 
increased medical resource utilization and costs (Davis et al., 2008).  
Treatment of Epilepsy 
The American Academy of Neurology, the American Epilepsy Society and the 
International League against Epilepsy have issued guidelines for the selection of 
pharmacologic therapy in patients with newly diagnosed epilepsy (French & Pedley, 
2008)(Table 1). For these diagnosed patients, treatment with an antiepileptic drug is 
commonly recommended, especially if further seizures might result in serious morbidity 
or mortality (Schmidt & Schachter, 2014).  Antiepileptic drugs should fully control 
seizures and be well tolerated with no long term safety problems, such as teratogenicity 
or hypersensitivity reactions (Schmidt & Schachter, 2014). The introduction of more than 
15 antiepileptic drugs since 1980 has provided choice, but selecting the optimum drug, 
brand or generic, requires balancing of advantages and limitations to meet the patient's 
needs (Schmidt & Schachter, 2014). 
Drug Safety 
Drug safety is a major public health concern in the United States and both patients 
and health care providers must make sound decisions and be well informed of the 





brand name prescription drugs continues to be examined in multiple randomized clinical 
trials conducted during drug development and Phase IV follow-up studies after FDA 
approval. Drug safety is the highest priority for patients and health providers, and the 
drug side effect profiles are key to many patients’ decision making about taking 
prescribed medications (Knapp et al., 2004).  
Conventional methods of drug safety surveillance involve literature searches and 
individual analysis of reports of adverse events. Currently, the FDA data mines utilizing 
tools such as the Multi-item gama poisson shrinker (MGPS) in combination with their 
adverse event reporting system database (Ohno-Machado, 2015). In 2007, FDA Public 
law no: 110-85 mandated the use of observational data as part of the active drug safety 
surveillance system (FDA, 2015).  These data sources explore pharmacoepidemiologic 
evaluation studies, yet statistical methods for screening observational data to generate 
hypothesis about potential drug effects have not been rigorously explored across 
mainstream data sources (Schneeweiss & Avorn, 2005). 
Problem Statement  
Epilepsy is a common neurological problem affecting 1-2% of the U.S. 
population, and has significant social and economic consequences, which can be 
minimized by optimal seizure control (McAuley et al., 2009). Medical research on 
epilepsy has explored the complexity of pharmacotherapy and has revealed intrinsic 
consequences from the pharmacokinetic and pharmacodynamic effects of medicating 
epileptic patients. Of particular concern is the increase in the number of prescriptions for 
patients aged 65 and older (Kohli & Bueller, 2013). Antiepileptic drugs provide 





drug treatment requires careful risk benefit analysis (Schmidt, 2009). Generic products 
are thought to be therapeutically interchangeable with brand name products and represent 
a cost effective alternative (Motola & DePonti, 2006). A controversial topic is the generic 
substitution of AED drugs, their interchangeability and equivalency to the brand name 
version. A growing number of observational studies have compared patients with 
epilepsy being treated with brand name AEDs to those patients switched to generics to 
determine seizure control and adverse events (Meyer et al., 2013), yet the results of these 
studies are conflicting (Yamada &Welty, 2011).  
The purpose of this study is to examine: 1) the extent to which generic switch is 
practiced for privately insured US patients; 2) variations in adherence to AED 
medications for patients by brand name and generic AED; and 3) to assess medical 
outcomes of patients on generic or brand name AEDs. 
The Importance of the Study for Population Health 
 
Opportunities exist in the pharmaceutical, educational, and health care industries 
to assist research and public policy leaders to improve prescribing medication practices 
for epilepsy. Previous research has yielded mixed findings as to whether generic drugs 
are therapeutically interchangeable with their brand name counterpart. The present study 
is intended to contribute to the literature on the current topic of generic and brand 
medication switch in patients with epilepsy, as well as to help clarify issues that must be 
considered when requiring the use of generic drugs. 
 This study will investigate the differences in medication compliance between a 





within this drug classification, and medical care outcomes for these patients using a 
large data set that reflects current practice in the US. The results will help inform the 
debate about regulations needed to circumscribe the practice of switching between 
brand-name and generic drugs for epilepsy. The results described here may also enable 
health care professionals to assume proactive roles in the initiation of a prescription 
drug reform for a special patient population, such as epilepsy. Furthermore, this 
analysis may contribute to the overall body of knowledge about important interactions 
between a common approach to cost savings and population health. 
This study is both important and timely, as the topic of generic switching has 
become politically contentious, with some US states having recently passed AED 
specific legislation requiring informed consent from the prescriber and the patient raising 
concern about the safety of generic drugs (Kesselheim et al., 2010). 
To better inform this issue, we will examine specific factors associated with the 
use the antiepileptic brand drug Dilantin® manufactured by Pfizer, comparing 
compliance rates for Dilantin® to those for the generic Phenytoin in 19-64 year old 
patients who have private insurance. Data from the MarketScan® database for 2013 will 
be used to examine switching behavior and medication adherence as measured by 
medication possession ratios, as well as medical care use in a one year period.  
Hypotheses: 
H1: Patients on generic Phenytoin have higher switch rates than patients on Dilantin® 





a six month period than patients on branded Dilantin® 
H3: Patients with lower medication possession ratios will be more likely to have 






Chapter 2: Literature Review 
Overview 
A literature review was conducted to expand on the background and need for this 
study, analyze previous research, and review other study designs. The primary objectives 
of the literature review were to explore generic and brand drug interchange in the 
treatment of epilepsy, and to inform optimal study design.  
Criteria for Selection of Literature 
PubMed, Ovid, Scopus, and Google Scholar databases were searched for relevant 
articles for inclusion in this literature review. Three types of terminology were used in the 
completion of the literature search: (1) terms related to seizure treatment including: 
antiepileptic drug, anticonvulsant, Dilantin®, Phenytoin and (2) terms related to drug 
equivalency including: bioequivalence, substitution, and (3) the generic articles that had 
key words including each of the different search terms utilized were selected based on 
inclusion of human data, and published between 2008 and the present.  
Significance of Epilepsy 
      It is estimated that 2 million people in the United States have epilepsy (CDC, 2015) 
and a recent report indicates that over 90% of patients with a seizure diagnosis have taken 
at least one drug for AED (CDC, 2015). Epilepsy is one of many chronic diseases in 
which medication non-adherence is problematic. Studies estimate that between 30% and 
60% of patients with epilepsy are non-adherent to their drug regimen, which can lead to 
higher seizure recurrence and increased medical resource utilization and costs (Davis et 





The FDA considers an approved generic product to be interchangeable with its 
brand counterpart as long as the mean area under the curve (AUC) and maximum 
concentration (C-max) are within 80-125% of the brand product (FDA, 2015). Generic 
drugs possess the same active ingredients, dosage form, strength, route of administration 
and labeling to meet the FDA’s approval standards without repeating Phase I, II, III 
clinical trials conducted by the original manufacturers (Kesselheim & Gagne, 2015).  The 
FDA also maintains that all approved generic products are bioequivalent to each other, 
even though bioequivalence studies comparing generic AEDs are not always undertaken 
(Davit et al., 2009). As a result, stakeholders in the neurology community have explored 
generic substitution from the brand Dilantin® and have concluded that this practice may 
place patients with epilepsy at risk for loss of seizure control. The practice of switching a 
name brand medication for a generic one in patients with epilepsy is also discouraged by 
the American Epilepsy Society and the American Academy of Neurology (Kinikar et al., 
2012). These organizations suggest that formulary driven generic interchange of AED 
medications should be avoided. Various health care payers have employed payment 
initiatives to drive down costs by incentivizing providers to increase the percentage of 
generic drugs used (Galanter, 2014). 
Treatment Compliance 
Leading authors in the field, such as Van Paesschen et al. (2008), Shin et al. 
(2014), Kesselheim et al. (2010), and Berg et al. (2008) agree that treatment failure of 
AED generic substitution can lead to a lack of treatment compliance, breakthrough 
seizures, bodily injuries, and job loss as several of the potential risks. The existing 





including Carbamazepine, Valproate, and Primidone, where some authors note wide-
ranging variability in the bioavailability of these drugs, unlike other classes of chronic 
disorder medications (Berg et al., 2008; Kesselheim et al., 2010; Van Paesschen et al., 
2008; Shin et al., 2014). Other factors, such as baseline seizure count and medication 
attitude influence the patient’s perception of seizure control, and can affect the patients’ 
decision making with regard to whether or not to switch to a generic AED medication 
(Bautista et al., 2011). Factors which may be involved in altering bioequivalence of 
generic drugs compared to brand name versions include low water solubility, narrow 
therapeutic window and drug interactions (Sankar et al. 2010). Non-bioequivalence of 
generic medications is thought to come primarily from differences in the manufacturing 
process, causing variability of the bioavailability of the generic preparation (Patel et al., 
2012).  
Additional individual case reports identified in the current review of the literature 
have confirmed problems with generic AED’s such as Phenytoin, Carbamazepine, 
Valproate, and Primidone. Some authors attribute these problems to reduced 
bioavailability of the generic AED (Berg et al., 2008; Kesselheim et al., 2010; Van 
Paesschen et al., 2008; Shin et al., 2014). Continued studies attempt to demonstrate and 
specify the problems associated with the generic substitution of AED medications, a 
matter that is believed to be both underreported and underestimated. Therefore, it is 
important for researchers to establish knowledge regarding the level of breakthrough 
seizures and or side effects that occur after switching to a generic product (Van 
Paesschen et al., 2008). Clinical and observational studies have provided updates to the 





consequent failure of AED treatment can be promoted by generic substitution (Berg et 
al., 2008). Literature reviews by Kesselheim and colleagues (2010) and Yamada and 
Welty (2011) evaluated eight retrospective studies, which generally demonstrated that 
substitution of AED’s resulted in higher use of medical services in patients with epilepsy, 
with an apparent link between switching and increased incidences of seizure events 
associated with generic AED substitution (Hansen et al., 2013). However, individual 
study results remain inconclusive and conflicting, and thus additional evaluations of drug 
adherence following switching, and medical outcomes associated with generic switching 
are warranted. 
What is Known About the Issue? 
Epilepsy is a common and chronic disorder where lifetime treatment is often 
required. According to the latest estimates, about 1.8% of adults aged 18 years or older 
have had a diagnosis of epilepsy or seizure disorder (CDC, 2015). Concerns about 
medication cost and drug safety have increased, resulting in an increased notoriety 
regarding the clinical equivalence of generic drugs (Kesselheim et al, 2010). Helmers and 
colleagues (2010) report, in a retrospective analysis of over 33,000 patients, direct health 
care costs during periods of generic use versus brand AED medications were significantly 
higher. Epilepsy related medical costs were also higher during periods of generic 
treatment, representing 28% of all cause cost difference, due to increased utilization of 
both hospital and outpatient services (Helmers et al., 2010). As the use of generic anti-
epileptic drugs increases, the highly debated topic among healthcare professionals 
continues to raise concerns, and remains controversial. According to Crawford and 





1968 after reports of Phenytoin intoxication among patients with epilepsy, yet safety 
evidence for epilepsy prescribing is still not conclusive. Scientists have shown that a 
relatively small decrease in serum concentrations could result in break through seizures 
due to the narrow therapeutic range of AED medications (Shin et al., 2014). The FDA 
only requires bioequivalence testing for the original product and not of corresponding 
generic substitutions (FDA, 2015). Additionally, a positive or negative 20% difference in 
bioavailability is permitted when licensing generics compared with branded drugs, a level 
that may be acceptable for most drugs (Crawford et al., 1996). However, small changes in 
bioavailability of AEDs specifically may result in poorer control of seizures with 
potentially serious implications. There may also be a large difference in bioavailability 
among the range of generics, especially those generic AED medications that have a 
narrow therapeutic index, which in turn may affect clinical outcomes (Shin et al., 2014). 
Although a variety of concerns have been raised regarding the FDA requirements for 
bioequivalence, the most urgent appears to be clinicians’ belief that an 80-125% range is 
too broad for narrow therapeutic range conditions such as epilepsy (Berg et al., 2008).  
Consequently, a great deal of research has focused on the unreliability of 
interchanging brand name and generic AED medications, which has raised additional 
concern about the fact that more generic medications are being used. This increase in the 
use of generic medications is thought to be due to either expiry of patent protection, or 
because generics drugs are sold at prices below their brand name counterparts, and thus 
can contribute to reduced healthcare spending (Kesselheim et al., 2011).  Crawford 
(2006) reports that formulary committees, health policy makers, and consumer groups 





costs, yet the true costs of generic prescribing must also include the cost of additional 
hospital and physician visits and cost of treatment failure, which overall could offset the 
savings of the generics. 
Concern has been noted with regard to the role of the medical legal environment 
if adverse consequences arise from generic substitution, particularly when informed 
consent is involved (Crawford et al. 2006). The legal responsibility of the occurrence of a 
breakthrough seizure is complicated when the patient’s medication has been switched to 
another treatment, considered by regulatory authorities to be equivalent, without 
informed consent of the patient. Informed consent is a prerequisite to the inclusion in 
clinical studies, however not a legal obligation for switching preparations (Crawford et 
al., 2006), further complicating the issue of legal responsibility of any adverse effects.  
Prescription drug substitution is addressed in state legislatures.  Some legislation 
will support the use of generics while other bills have been submitted seeking to restrict 
substitution of certain classes of drugs, notably antiepileptic drugs and 
immunosuppressants (Shaw & Hartman, 2010).  There are variations in both existing and 
proposed legislation, but in general these bills aim to prohibit a pharmacist from 
substituting or interchanging any AED without prior notification and/or signed consent 











Antiepileptic Drug Substitution Legislation 
Hawaii   The pharmacist shall not substitute an equivalent generic drug for an 
AED except with consent of practioner and the patient.    Effective 2003 
Illinois   No pharmacy interchange of an AED without notification and 
documented consent of physician and patient.  Effective 10/29/07 
Tennessee  A pharmacist must provide notification to patient before interchange 
of AED as well as prescribing physician.  Effective 7/1/07 
            Utah   Pharmacist must notify practitioner prior to substitution whether AED is 
generic or brand drug. Effective 5/5/08    
                   (Shaw & Hartman, 2010) 
The Role of Phenytoin in Treatment of Epilepsy 
The treatment of epilepsy has a very broad degree of complexity which can be 
complicated by the unreliability of interchanging brand and generic AED medications. 
This study reviews Phenytoin, which has been the most widely used generic medication 
to treat seizures over the past twenty years, even though a variety of new compounds 
have been released (Das et al., 2013).  Phenytoin was first synthesized in 1908 at the 






Effect of Using Generics on Government Spending 
In 2007, the congressional budget office (CBO) examined the use of generic 
drugs in Medicare’s outpatient prescription drug benefit for senior citizens and people 
with disabilities (Part D), using the claims data from Centers for Medicare and Medicaid 
Services (CMS) plans for ten million prescriptions. At that time, about 65% of Part D 
prescriptions were filled with generics. The CBO’s goal was to analyze how much was 
saved as a result of the use of generic drugs, as well as assess the potential for savings 
associated with increasing the use of generics. The CBO also examined savings from 
generic substitution. Among Part D prescriptions, of those brand drugs that had a generic 
version available more than 90% were filled with the generic option (CBO, 2014). 
In a separate analysis by the Department of Health and Human Services (Office 
of Inspector General) generic drugs were dispensed 88% of the time when available 
(OIG, 2007). For Part D, there was a strong financial incentive to encourage the use of 
generic drugs, yet there was little data to reflect how the patients felt about the use of 
such generic drugs.  
Influence of Patient Illness on Perception of Generics and Brand 
     In addition to the prescribing habits and protocols of healthcare providers, decisions 
about the choice of generic or brand name medicines may also be influenced by 
patients’ perceptions and beliefs about treatment, side effects, as well as their illness 
(Figueiras et al., 2010). The literature suggests that patients develop beliefs about the 
necessity of a specific type of medication for maintaining their health status. 
Subsequently, beliefs about illness and medicines are interconnected, and may influence 





(1999), literature is scarce regarding how patients make decisions concerning their 
medications, or about their preferences for one drug or another. However, there is 
evidence that levels of knowledge about medicines in general may influence consumer 
attitudes and beliefs about medicines for particular illnesses (Horne & Weinman, 1999), 
suggesting that perceptions concerning efficacy and safety of generic prescriptions may 
depend on the medical condition being treated. Illness and treatment beliefs may also 
play a crucial role in patients’ decisions about the choice between generic and brand 
medicines (Figuerias et al., 2008). Figuerias (2008) and authors have argued that the 
nature of the illness threat is influenced by the illness label and the interpretation of 
symptoms. 
According to a study conducted by Dohle and Siegrist (2014), the consumers’ 
perceptions of an illness was the main determinant of satisfaction with generic drug use, 
rather than beliefs regarding the equivalence of brand versus generic medicine. Another 
study investigated whether consumers were more likely to utilize a generic medication 
or a brand prescription for minor or more serious health problems (Figuerias et al., 
2008). The results indicated that patients are less likely to take generic drugs for chronic 
and serious conditions like epilepsy, even when they have had positive experiences with 
them and believed they were equal in quality to brand name products (Figuerias et al., 
2008). Decisions not to take generics appeared to be driven by a fear of health loss, 
which increased with the seriousness of a disorder, rather than the belief that generics 
were in general equivalent to brand name drugs (Omojasola et al., 2012). These and 
other findings indicate that the consumer’s perception of their illness also influences the 





preferences for medicines may differ between the general population and those who 
experience a condition, we can assume that the perceptions of illness severity as well as 
patient beliefs and knowledge about medicines will all have an important roles in 
decisions about the use of generic or brand name treatments (Figueiras et al., 2010).  
Conceptual Model 
A review of the multidisciplinary literature on seizure outcomes following use of 
brand versus generic antiepileptic drugs reveals a lack of comprehensive theoretical 
framework for understanding these events and their complexities (Berg et al., 2008; 
Hansen et al., 2009; Shin et al., 2014). Berg (2008) argues that definitive evidence on the 
effects of generic AED medication substitution is lacking, and it is important for 
physicians to take more accountability, reporting any cases involving breakthrough 
seizures to the FDA directly. Conversely, other experts have pointed out that a 2010 
systematic review provided no evidence of loss of seizure control with generic 
substitution for many AED medications (Kesselheim et al., 2010). The topic itself is 
wrought with confusion, and studies indicate unclear consensus to guide clinicians 
(Privitera, 2013). Applying a process of conceptual framework analysis, as shown in 
Figure 1, will provide a theoretical framework to shed new light on the feasibility of 
implementing sustainable prescribing practices. This study will contribute important 
information to the current database on generic switch, and help clarify the issues that 







Figure 1: Representation of the conceptual framework developed for interpretation of 
proposed hypotheses.  
Past Studies 
Literature identified in this review suggests that the majority of studies have 
primarily relied on retrospective analysis to show increase in breakthrough seizure 
occurrence when switching from brand name to generic drug use in the treatment of 
epilepsy (Hansen et al., 2009; Kinikar et al., 2012; Shin et al., 2014; Zachry et al., 2009; 
Rascati et al., 2009; Labiner et al., 2010). However, several prospective studies have also 
found significant increase in pharmacokinetic outcomes affecting bioequivalence (Olling 
et al., 1999; Revankar et al., 1999). Several authors have reported an increase in 
switchback rates from generic to brand AED medications using claims databases as their 





A review of selected study designs suggests that the current approaches do not 
appear to have become more advanced or sophisticated over the years. Researchers have 
primarily applied existing case control designs and either longitudinal, prospective, or 
retrospective analysis (Yamada & Welty, 2011). Most trials identified by this search were 
short-term evaluations of small populations and were powered to assess differences in 
pharmacokinetic parameters rather than clinical outcomes (Kesselheim et al., 2010). 
Future studies could potentially improve external validity and generalizability based on 
the sampling model. Providing data about the degree of similarity between the various 
study groups utilizing different locations, people, and times of day might continue to 
frame the ability to generalize findings.   
The Next Step in Study Design 
Analyses of administrative insurance claims data to assess the prevalence of 
generic switches and adherence has been widely used in a variety of chronic disease 
studies. The utilization of claims data presents a good opportunity to provide information 
regarding patterns of medication dispensing and may be more generalizable than 
observational studies in controlled clinical trials (Kinikar et al., 2012). 
A limitation of current clinical research is that controlled trials are frequently 
comprised of participants that are not randomly selected, and therefore may be atypical of 
real world practice settings (Davis et al., 2008). Data may then be viewed as non-
representative of the general population, and study design must be augmented in some 
way to address this matter. To this end, it is recommended that future studies of 
administrative data to assess medication adherence of generic AED medications are 





It should be further noted that there is also a pressing need for additional studies 
to determine whether there is bioequivalence and therapeutic equivalence between the 
brand name medication Dilantin® and the generic medication Phenytoin, both of which 
are currently available in the market (Jankovic & Ignjatovic Ristic, 2014). Currently, the 
FDA (2015) states that there is no adequate data indicating that current testing for generic 
medications is faulty, even with drugs that have narrow therapeutic range conditions. It is 
unclear if reported problems are due to underreporting, or if there is actually no problem 
to report with generic preparation of AED medications (Berg et al., 2008). Some drug 
products may have unique structural or functional attributes that necessitate product 
specific approaches to therapeutic equivalence determinations (Kesselheim & Gagne, 
2015). Tests to demonstrate therapeutic equivalence following generic approval using 
product-specific pathways along with active surveillance studies would be useful in 
promoting appropriate use of lower cost generic drugs (Kesselheim & Gagne, 2015).  
This is a critical issue that warrants further review.  
This study provides a unique opportunity to assess the extent of non-adherence 
and or generic switch behavior with currently approved generic AED medications within 
a managed care environment. There is a potential opportunity to extrapolate the 
association between AED medication non-adherence and future healthcare utilization. In 
addition, the identification of specific factors associated with the occurrence of increased 
seizures and adverse effects when switching from brand name to generic AED 
medications will provide insight into the potential ways in which positive healthcare 
behaviors may be fostered, and result in decreased utilization of outpatient and hospital 





health policymakers to better identify instances where prescribing brand AED 
medications would improve patient outcomes.  
We use a retrospective analysis of archival statistics utilizing data from the 
MarketScan® database for 2013, which contains all billing records for approximately 
four million covered individuals. It will be used to examine switching behavior and 
medication adherence as measured by medication possession ratios in patients with 
epilepsy. Selection bias will be controlled through statistical modeling. 
Summary 
 Chapter 2 provided a review of relevant literature. An overview of relevant 
material to the research study at hand was presented, and the implementation of a 
conceptual model was discussed, along with the necessity for its use. The different study 
designs used in research related to this field of study were reviewed, and the issues with 
past study designs were discussed. Information was pulled from these studies regarding 
the recommended course of action for future study designs. The criteria for the selection 
of literature included within this review are presented. Chapter 3 will offer a description 






Chapter 3: Methodology 
Study Objective 
A retrospective cross sectional analysis of administrative data about the utilization 
of generic and brand medications in epilepsy and seizure disorder was conducted. Large 
health care utilization databases are frequently used in variety of settings to study the use 
and outcomes of therapeutics. Their size allows the study of infrequent events, and their 
representativeness of routine clinical care makes it possible to study real-world 
effectiveness and utilization patterns (Schneeweiss 2005).  
This study’s primary objectives are to examine: 
1) The extent to which generic switch is practiced for privately insured US 
patients; and 
2) Variations in adherence to anti-epileptic medications (AEDs) for patients 
switched from brand name and generic AEDs.   
3) Medical care use for patients on brand name and generic AEDs. 
Hypotheses 
     We hypothesize that: 
● H1: Patients on generic Phenytoin will have higher switch rates than patients on 
Dilantin® 
● H2: Patients on generic Phenytoin will have lower medication possession ratios 





● H3: Patients with lower medication possession ratios will be more likely to have 
medical care use indicative of seizure activity 
For the purposes of this study, the use of the antiepileptic brand drug Dilantin® 
manufactured by Pfizer will be assessed to measure these effects, and the rates of 
compliance will be compared for Dilantin® and the generic medication Phenytoin in 19-
64 year old privately insured patients. Data from the MarketScan® database for 2013, 
which contains all billing records for approximately four million covered individuals, will 
be used to examine switching behavior and medication adherence as measured by 
medication possession ratios.  
Data Collection  
The Medical University of South Carolina (MUSC) College of Health Professions 
(CHP) purchased rights to the use of the Truven Health Analytics MarketScan® database. 
The SAS statistical system was used to gather and summarize the data and then present 
for analysis to this author.  
The blinded dataset lacks personal health information linked to any specific 
patient. Due to the data's lack of individual identifiers, the MarketScan® data was 
deemed Non-human research by the Medical University of South Carolina Institutional 
Review Board. 
Data Population 
The International Classification of Diseases-9-Clinical Modification (ICD-9-CM) 
codes were used to search the Marketscan® National database. Patients with the ICD-9-





as the primary inclusion criteria. The new data set was refined by selecting from patients 
who had the following ICD-9-CM codes:  345.9, 345.0, 345.1, 345.4, 345.5. All 
information from the SID databases for each patient was carried over to the new 
database, respectively.  Multiple hospitalizations for the same individual counted as 
separate occurrences. 
De-identified patient data were included in the analysis if they (1) were prescribed 
Phenytoin for seizure disorder, (2) experienced some form of interchange through the use 
of at least one generic Phenytoin prescription in 2010, (3) were at least 19 years of age or 
older at the time the medication interchange occurred, and (4) had a continuous 
membership in their primary insurance plan for six months before and after the 
medication interchange. Patients were excluded if they received Phenytoin for 
neuropathy or for a pain diagnosis, as opposed to being prescribed the drug for a seizure 
diagnosis. The data for the sample was extracted using the following final diagnosis for 
any patient in the dataset: ICD-9-CM coded encounter of a seizure disorder: 345, 345.9, 
345.0, 345.1, 345.4, 345.5 
Description of Variables 
The project independent variable was the brand Dilantin® or generic Phenytoin 
medication. The first dependent (y) variables are that of medication possession for each 
of the following: 
1. Generic Phenytoin switch - Yes/No 







The dependent variables identified for a medical care use were: 
1. General admission to inpatient hospital (may or may not seizure related) 
2. Hospital inpatient admission due to seizure 
3. Outpatient visit due to seizure 
4. Emergency department (ED) visit due to seizure 
Data Set and Statistical Methods 
The raw dataset contained exposure and outcome variables for 6681 patients 
followed for 1 year. Data collected from patients on generic Phenytoin or brand name 
Dilantin® were used to determine which of these patients had higher switch rates, 
medication possession ratios, and medical care events. The following statistical analyses 
were conducted: summary statistics are reported as numbers and percentages for 
categorical variables and medians and ranges for continuous variables. For hypothesis 1, 
Chi-square tests were used to assess statistical significance between groups. Logistic 
regression was used to calculate odds ratios, confidence intervals and P-values. This 
analysis assessed which patient classes had higher switch rates. For hypothesis 2, the 
Kruskal- Wallis nonparametric test assessed the difference in average medication 
possession ratios for four groups of treatment switched or non-switched patients. This 
analysis determined if patients on generic Phenytoin had lower medication possession 
ratios than patients on branded Dilantin®, and if switching from one treatment to another 
affected medication possession ratios over a one year period.  
Groups were defined as follows: 
Group 1: Start on Generic, end on Generic 





Group 3: Start on Dilantin®, switch to Generic 
Group 4: Start on Dilantin®, end on Dilantin®  
 
For hypothesis 3, medication possession was the exposure variable and the 
analysis assessed whether patients with lower medication possession ratios were more 
likely to have medical care use indicative of seizure activity. Specifically, compliance 
was defined for a patient with a ratio > 1 and non-compliant had a ratio < 1. Logistic 
regression and poisson regression were used to calculate odds ratios and relative risk, 
respectively. The outcomes we identified were as mentioned above: inpatient admissions, 
epilepsy related inpatient admissions, outpatient visits, and ED visits. 
Study Importance 
The studies investigating bioequivalence and interchangeability of brand name 
and generic anti-convulsant drugs are sparse, and their results are conflicting. Few studies 
have investigated change in seizure control after switching from brand name drugs to 
generic medications, a central question in the field of research and treatment. Steady state 
plasma concentrations of anticonvulsants and their fluctuations are directly linked to 
seizure control, so a study that explores therapeutic equivalence of brand name and 
generic was needed. This study provides insight into the "switchability" issues of brand 
name and generic anticonvulsants. It serves to provide clinicians with useful data to 
evaluate and take into consideration when prescribing anticonvulsants to their patients 
with epilepsy, and those patients who are being considered for a switch from brand 





current knowledge of effects of generic switches, and help clarify issues that must be 
considered when requiring or suggesting the use of generic drugs.  
Limitations 
The key limitation of this study is the utilization of administrative claims data. 
Administrative database research creates potential risks that can make the study 
uninterpretable or biased (Walraven 2012).  Concerns about database studies include data 
validity, lack of detailed clinical information, and a limited ability to control confounding 
variables (Schneeweiss & Avorn, 2005). While most guidelines for assessing the validity 
of observational studies apply to administrative database research, the unique 
characteristics of this data source must be accounted for in the study design to avoid 
results that are biased or uninterpretable (van Walraven et al., 2012). Minimization of risk 
by providing robust description of data and variables utilizing ICD-9-CM codes will be 
important. Employing quality criteria to ensure the accuracy of diagnostic and procedural 
codes, distinguishing between clinical and statistical significance and analyzing data 
properly to explore the influence of population definitions on study outcomes is key to 
providing valid and useful results (van Walraven et al., 2012).  Physician beliefs and 
prescribing ability to treat epilepsy could influence the patient’s outcomes, thus it is 
likely that within provider correlation may exist. This effect must be examined using 
statistical methods that control for within provider correlation, if needed. The adoption of 
evidence based clinical care pathways and increased education evolves from the strength 
of the study and the ability to generalize the results. Accuracy of administrative data is 
dependent on the accuracy of the physician documentation as well as the skill of the 





disorder and epilepsy can be used with similar frequency, and including both terms to 
identify patients with this condition is recommended (Tu et al., 2014).  This study is 






Chapter 4: Results 
Hypothesis 1 
Data were analyzed using statistical software (R®; Vienna, Austria). The total 
number of patients identified as having epilepsy or epileptic syndrome, as well as 
currently prescribed generic Phenytoin or Dilantin® in the MarketScan® database were 
6681. For H1, logistic regression was conducted to examine the difference in switch rates 
between patients who started treatment on Phenytoin versus those who started treatment 
on Dilantin®. Of the 6681 patients identified, 4704 patients started treatment with 
Phenytoin, and 1977 patients began their treatment with Dilantin®. Data show that 6312 
of these patients did not switch treatments, while 369 patients had switched, resulting in a 
5.5% switch rate in this sample overall. Within the group who started treatment on 
Phenytoin, 4566 patients did not switch and 138 patients switched, a switch rate of 2.9%. 
The switch rate for the group of patients who started on Dilantin® was 11.7%, where 
1746 patients did not switch from Dilantin®, and 231 patients did switch. A Pearson’s 
Chi-squared test with Yates’ continuity correction revealed a significant difference in 
switch rates between patients who started treatment on Phenytoin compared to those who 
started on Dilantin® χ2 (1, N = 507) = 202.60, p < 0.001. Patients who began treatment 
on Dilantin® were more likely to switch treatments than those who started their treatment 
with Phenytoin. The difference between these rates was statistically significant (OR = 
4.38, 95% CI [3.52-5.44], p < 0.001) and can be seen in Figure 2. Additional data from 






Figure 2: Results of logistic regression analysis on medication switch rates among 
epilepsy patients who began treatment on generic Phenytoin, compared to those who 
began treatment on Dilantin®. The analysis revealed significant differences in switch 













Logistic regression coefficients of prescription switch rates in epileptic patients 
prescribed generic Phenytoin or Dilantin® in 2013 
Independent variable Estimate Std. error z value p-value 
Phenytoin -3.50 0.09 -40.50 p < 0.001 
Dilantin® 1.48 0.11 13.28 p < 0.001 
     
χ2 202.60   p < 0.001 
OR (95% CI) 4.38 (3.52-5.44)   p < 0.001 
df 1    
N 507    
 
Hypothesis 2 
A (non-parametric) logistic regression was conducted on the data for H2, which 
also yielded highly significant results. The overall distribution of the sample can be seen 
in Figure 3. For this hypothesis, data from the 6681 identified patients in the 
MarketScan® database was used to compute medication possession ratios for each group 
of interest (Group 1: Start on Generic, end on Generic; Group 2: Start on Generic, switch 
to Dilantin®; Group 3: Start on Dilantin®, switch to Generic; Group 4: Start on 
Dilantin®, end on Dilantin®). The median medication possession ratio for the total 
sample (N = 6681) was 99.4 (IQR = 79.65-107.80). The numbers of patients in each 





patients, Group 4: 1746 patients. The analysis showed significant differences in rates of 
compliance, as measured by possession ratios, among the groups; Group 1: Mdn =  98.21, 
IQR = 76.92-107.20, Group 2: Mdn =  98.41, IQR = 69.45-113.70, Group 3: Mdn =  
100.30, IQR = 86.56-111.40, Group 4: Mdn =  101.7, IQR = 86.96-108.30, p <0.001. This 
data suggests that patients who start treatment on Dilantin® and stay on Dilantin® are the 
most compliant, while those who start on Phenytoin and switch to Dilantin® are the least 
compliant. Additionally, Figure 4 shows that both groups who started treatment on 
Dilantin® were more compliant than those starting treatment on Phenytoin.  As can also 
be seen in Figure 4, the greatest variability in medication compliance, as measured by 
medication possession ratios, occurred in Group 2 patients who had switched from 
generic Phenytoin to Dilantin® (IQR = 69.45-113.70), followed by those patients in 
Group 1 who were taking generic Phenytoin only without switching (IQR = 76.92-
107.20). Alternatively, the least variability in compliance was seen in Groups 4 and 3, the 
Dilantin® only group (IQR = 86.96-108.30), and the Dilantin® switched to Phenytoin 
group 3 (IQR = 86.56-111.40), respectively. This suggests that patients who began 
treatment with Dilantin® overall showed less variability in compliance than those who 
started treatment on Phenytoin. Finally, these data also reveal unexpected findings with 
regard to outliers. Group 1 and Group 4 had the greatest number of outliers, followed by 
Group 3. However, all groups with the exception of Group 4, contained outliers only in 
the direction of lesser compliance. Group 4 (treated with Dilantin® only) is the only 
group to contain outliers that reached and exceeded the target compliance. This means 





outlying patients from this group were uniquely exhibiting 100% compliance with their 
medication regime.   
 
 
Figure 3. Histogram representing the overall distribution of computed medication 
possession ratios for the total sample (N = 6681) of epileptic patients prescribed generic 
Phenytoin or Dilantin® in 2013. The data is not normally distributed, leading to the use 
of non-linear logistic regression analyses. A large number of patients are non-compliant 







Figure 4. Box plot representation of compliance rates, as measured by medication 
possession ratios, for epilepsy patients in all four groups over one year (2013). Group 1, 
Gen/Gen includes patients who started treatment on generic Phenytoin and ended on 
generic Phenytoin (no switch from generic Phenytoin); Group 2, Gen/Dil includes 
patients who started treatment on generic Phenytoin and ended on Dilantin® (switched 
from generic Phenytoin to Dilantin®); Group 3, Dil/Gen included patients who started 
treatment with Dilantin® and ended on generic Phenytoin (switched from Dilantin® to 
generic Phenytoin); Group 4, Dil/Dil includes patients who started treatment on 
Dilantin® and ended on Dilantin® (no switch from Dilantin®). The dashed horizontal 





indicate the median value for each group. Red boxes represent the extent of the 




Logistic regression analysis of medication possession ratios in epileptic patients by 









1 (n = 4566) 0.00 76.92 98.21 88.12 107.20 148.00 30.26 
2 (n = 138) 17.96 69.45 98.41 91.70 113.70 147.10 30.76 
3 (n = 231) 0.00 86.56 100.30 96.28 111.40 142.40 23.36 
4 (n = 1746) 0.00 86.96 101.70 95.61 108.30 148.00 23.92 
        
Kruskal-Wallis 
χ2 73.46      
 
Df 3       
p-Value 
p < 
0.001      
 






Dichotomized Variable Analysis 
Total Sample 
The third hypothesis tested various medical outcomes associated with compliance 
as measured by medication possession ratios. Data for the overall sample was initially 
dichotomized by “compliance” and “non-compliance”, where patients were coded 0 
(compliant)  if their medication possession ratio was ≥ 100, and coded 1 (non-compliant) 
when their medication possession ratio was < 100, 100 therefore being the target value 
indicating 100% compliance. This revealed that from the total sample of 6681 epilepsy 
patients prescribed generic Phenytoin or Dilantin®, there were a 3216 compliant and 
3465 non-compliant patients. This dichotomization was also confirmed by analyses for 
each group (Compliant: Mdn = 108.1, IQR = 103.70-116.40; Non-compliant: Mdn = 
80.84, IQR = 56.57-92.44) 
 Of the 6681 patients in the total sample, data from MarketScan® reported 642 
patients requiring in-patient hospital admissions, 173 patients with epilepsy related 
admissions, 433 patients having had outpatient visits, and 5832 attending the emergency 
department (ED).  
 The mean number of ED visits was similar among compliant and non-compliant 
patients, M = 1.9 and M = 2.15, respectively. However, the range of ED visits showed 
variability, with a greater range in the number of ED visits for non-compliant (range = 
0.00-37.00) patients than for compliant patients (range = 0.00-19.00). Over a one year 





for the non-compliant patients with an overall average of approximately two emergency 
room visits for both groups with a slight increase in the non-compliant group. 
In-Patient Visits by Compliance 
 Logistic regression analyses and Pearson’s Chi-squared tests were used to assess 
the dichotomized variable data. Data from the MarketScan® database for 2013 showed 
that 233 of the 3216 compliant patients required in-patient hospital admissions, compared 
to 409 of the 3465 non-compliant patients. These values result in a 7.25% admission rate 
for compliant patients, and an 11.80% admission rate for non-compliant epilepsy patients, 
a difference that was statistically significant, χ2 (1, N = 442) = 39.38, p < 0.001. Logistic 
regression showed that non-compliant patients were 71% more likely to require in-patient 
services than compliant patients, OR = 1.71, 95% CI (1.45-2.02), p < 0.001. These results 






Figure 5. In-patient admission rates for compliant and non-compliant epileptic patients, 












Logistic regression coefficients of inpatient visits in compliant and non-compliant 
epileptic patients prescribed generic Phenytoin or Dilantin® in 2013 
Group Estimate Std. Error z value p-Value 
Compliant -2.55 0.07 -37.48 p < 0.001 
Non-compliant 0.54 0.09 6.26 p < 0.001 
 
Epilepsy Related Hospital Admissions by Compliance 
 Data was also collected from the MarketScan® database regarding the number of 
epilepsy related hospital admissions for compliant and non-compliant epileptic patients 
prescribed Phenytoin or Dilantin® in 2013. These data showed that 58 compliant 
epileptic patients had epilepsy related hospital admissions during the one year period, 
while 115 non-compliant patients were admitted for epilepsy related reasons during the 
same year. The admission rates for compliant vs. non-compliant patients were 1.80% and 
3.32%, respectively. This difference was statistically significant, χ2 (1, N = 173) = 14.59, 
p < 0.001. As is shown in Figure 6, non-compliant patients were 87% more likely to have 
had an epilepsy related hospital admission than compliant patients, OR = 1.87, 95% CI 






Figure 6. Epilepsy related hospital admission rates for compliant and non-compliant 
patients, according to medication possession ratios. These data were statistically 











Logistic regression coefficients for epilepsy related hospital admissions in compliant and 
non-compliant epileptic patients prescribed generic Phenytoin or Dilantin® in 2013 
Group Estimate Std. Error z value p-Value 
Compliant -3.99 0.13 -30.17 p < 0.001 
Non-compliant 0.63 0.16 3.84 p < 0.001 
 
Outpatient Visits by Compliance 
 Poisson regression was used to analyze the data on outpatient and ED visit data 
described below. Data on the number of outpatient visits in 2013 showed 188 episodes of 
outpatient visits for compliant epilepsy patients as a group. Non-compliant patient data 
revealed that 439 episodes of outpatient visits were required in this group. Data also 
revealed that, for compliant patients, the incidence rate of outpatient visits was 58 per 
1000 person years; for the non-compliant patients, the incidence rate of outpatient visits 
was 127 per 1000 person years (RR = 2.17, 95% CI [1.83-2.57], p < 0.001). This data 
suggests that if 1000 compliant patients were followed for one year, there would be a 
total of 58 outpatient visits within that year. Alternatively, for 1000 non-compliant 
patients, the total number of outpatient visits would equal 127 in one year. This also 
suggests that non-compliant patients have greater than twice the risk of requiring 





were statistically significant. Poisson regression coefficients are shown in Table 7. 
  
Figure 7. Incidence rates of outpatient visits for compliant and non-compliant epileptic 











Poisson regression coefficients for outpatient visit incidence rates in compliant and non-
compliant epileptic patients prescribed generic Phenytoin or Dilantin® in 2013 
Group Estimate Std. Error z value p-Value 
Compliant -2.84 0.07 -38.93 p < 0.001 
Non-compliant 0.77 0.09 8.87 p < 0.001 
 
Emergency Department Visits by Compliance 
 The number of ED visits in 2013 for compliant and non-compliant epilepsy 
patients were alarmingly high. Compliant patients exhibited 6110 ED visits overall as a 
group, while non-compliant patients attended the ED 7440 times as a group within this 
one year period. The incidence rates of ED visits for compliant and non-compliant 
patients were 1900 and 2147 per 1000 person years, respectively (RR = 1.13, 95% CI 
[1.09-1.17], p < 0.001). This data, represented in Figure 8, also suggests that non-
compliant patients have a 13% greater risk of attending the ED than do compliant 
patients. These results were also statistically significant, and corresponding Poisson 






Figure 8. Incidence rates of emergency department visits for compliant and non-











Poisson regression coefficients for emergency department visit incidence rates in 
compliant and non-compliant epileptic patients prescribed generic Phenytoin or 
Dilantin® in 2013 
Group Estimate Std. Error z value p-Value 
Compliant 0.64 0.012 50/17 p < 0.001 
Non-compliant 0.12 0.017 7.09 p < 0.001 
 
Continuous Variable Analyses 
In-patient Visits 
Logistic regression analyses were used to assess the continuous variable data for 
medication possession from the MarketScan® database for 2013. These analyses revealed 
that a 1% positive change in compliance resulted in a statistically significant 1% decrease 
in the number of in-patient hospital admissions, OR = 0.99, 95% CI (0.98-0.99), p < 
0.001. Additionally, a 10% positive change in compliance corresponded to a 12% 
decrease in in-patient hospitalization which was also statistically significant, OR = 0.88, 
95% CI (0.86-0.90), p < 0.001. 
Epilepsy Related Hospital Admissions 
 Analyses of the continuous variable medication possession with regard to epilepsy 
related hospital admissions also showed statistically significant results. A 1% positive 
change in compliance resulted in a 2% decrease in epilepsy related hospital admissions, 





related to a 16% decrease in epilepsy related admissions, OR = 0.84, 95% CI (0.81-0.88), 
p < 0.001.  
Outpatient Visits  
 Continuous data on outpatient visits indicated that a 1% positive change in 
compliance resulted in a statistically significant 1% decrease in the number of outpatient 
visits (OR = 0.99, 95% CI [0.98-0.99], p < 0.001), while a 10% positive change in 
compliance resulted in a 13% decrease in outpatient visits which was also statistically 
significant (OR = 0.87, 95% CI [0.85-0.89], p < 0.001).  
Emergency Department Visits 
 Logistic regression conducted on the data regarding the number of ED visits in 
epilepsy patients revealed that a 1% positive change in compliance corresponded to a less 
than 1% decrease in the number of ED visits, yet this change was statistically significant, 
OR = 1.00, 95% CI (1.00-1.00), p < 0.001. A 10% positive change in compliance resulted 
in a statistically significant 3% decrease in ED visits, OR = 0.97, 95% CI (0.96-0.97), p < 
0.001. These data, despite their significance, suggest that ED visits may be the least 






Chapter 5: Discussion 
Substantial concerns continue to be expressed about potential problems arising 
from switching epileptic patients between generic and brand AED drugs. This study was 
designed to provide an assessment of brand name Dilantin® and generic Phenytoin, 
comparing switch rates, compliance, and seizure related outcomes, as there is growing 
concern about the efficacy and safety of generic AED’s (Haskins et al., 2005). Changing 
health policy and managed care practices focus on cost containment and may encourage 
the use of generics because they are less expensive than their branded counterparts. What 
may be greatly underestimated are the additional unexpected costs associated with 
switching drugs which can cause both an increase in adverse events and increased 
medical use, such as hospitalization and emergency room visits. 
Results from this large managed care database demonstrated that patients treated 
with Phenytoin had a switch rate of 2.9%, while those patients who started treatment on 
Dilantin® showed a switch rate of 11.7%.  These initial results appear to support the 
body of evidence suggesting that patients who begin treatment on a branded AED (i.e. 
Dilantin®) are more likely to switch treatment to a generic. However, an unexpected 
finding in our study suggests that those who start on Phenytoin and switch to Dilantin® 
are the least compliant compared to other groups in our analyses, as measured by 
medication possession ratios. Study investigators initially hypothesized that switches 





switch showed the opposite effect and is inconsistent with previous studies conducted in 
this area. The greatest rates of compliance were evident in the Dilantin® treated patients 





one year review period. In a recent study, Gagne (2015) showed differing results 
with regard to brand/generic interchange, and  reported confirmation that generics were 
more effective than their brand counterparts. Gagne (2015) provided opposing evidence 
that adherence was better for generic AED’s than their branded versions, and better 
medication adherence was associated with better patient outcomes. 
In the present study, a confirmed relationship between brand or generic AED’s 
and compliance, inpatient hospital use, outpatient services, and ED visits was established. 
Non-compliant patients were 71% more likely to require in-patient services than 
compliant patients, hadgreater than twice the risk of requiring outpatient services than 
compliant patients, and were  at a 13% greater risk for attending the ED than compliant 
patients. These results are in line with previous research such as observational studies by 
Zachry et al. 2009, which provide further  evidence that AED substitution may increase 
use of health care services (hospitalization, ED) and strengthen the association between 
switching and adverse outcomes. 
 Equally important is the attention given to the complexity of pharmacokinetics 
between brand and generic AED’s. This influence has proven to be critical to the 
implication of AED switching. In 2011, a systematic review of the current evidence on 
generic substitution of AEDs was conducted by Yamada and Welty (2011), including a 
retrospective and prospective controlled study analysis of generic substitution of AEDs. 
The authors found that the majority of past retrospective studies had indicated that 
generic AED substitution resulted in higher use of medical services in patients with 
epilepsy. Similarly, our study also suggests that switching to generic may be associated 





It is important to ensure that patients, pharmacists, prescribers and policy decision makers 
are aware of the potential risks of AED switching. 
Although the present study had some limitations, our analyses support the 
existence of viable concerns and challenges associated with AED switching, for both 
patients and health care providers. Until formal guidelines are administered by regulatory 
authorities, many epilepsy patients will continue to experience the negative effects of 
AED switching. It is clear from our literature review and previously conducted research 
that many physicians are concerned about the efficacy and safety associated with 
unhampered substitution of generic AEDs, but may inaccurately underestimate how often 
generic substitution occurs (Wilner, 2002). Policies that include mandatory substitution 
or substitution without informed consent to both patient and provider are clearly 
passionate topics and warrant further discussion (Maliepaard et al., 2009). Strong 
recommendations regarding generic substitution from The Epilepsy Society and The 
American Academy of Neurology as well as other advocacy and medical authorities 
detail anecdotal evidence as well as clinical concerns regarding generic substitution. 
Several states have issued laws regarding generic substitution, while other states are 
considering implementation of similar legislation (Meyer et al., 2013). These groups aim 
to scrutinize the need for continued robust studies to evaluate generic AED substitution, 
and to directly examine the clinical effects of brand to generic substitution in controlled 
trials. Supplementing the existing body of knowledge, The Agency for Healthcare 
Research and Quality conducted a comparative effectiveness review in December 2011 
which evaluated the effectiveness and safety of AEDs in patients with epilepsy. The 





differences in benefits or harms associated with the use of generics versus brand name 
products (Talati et al., 2011). The review also acknowledges that switching from a brand 
name AED to a generic AED may increase health care utilization, but recognizes that 
“this is based on controlled observational study data, which has inherent limitations 
substantially reducing the strength of evidence” (Talati et al., 2011). 
Study Considerations and Recommendations 
The results of this study provide additional substance and contributory evidence 
regarding epilepsy treatment, switching, and associated medical events, yet has its 
limitations. The first major limitation was the use of observational data from a managed 
care database, and not utilizing a randomized controlled trial design which might have 
included additional patient data such as disease characteristics, seizure frequency, disease 
duration or patients identified on multiple AED’s. Our research falls short of specifically 
identifying whether generic AED’s directly affect the risk of breakthrough seizures, 
however does include important results regarding compliance and medical care use. This 
study reinforces evidence showing that when an AED formulation switch occurs, 
additional patient monitoring is necessary and patients should be considered individually 
regarding the appropriateness for changes in treatment formulation. There remains 
important considerations when substituting AED’s as compared to other chronic or acute 
medications that need to be underscored. It is clear that further clinical studies are needed 
to determine outcomes or possible pitfalls of generic substitution to guide treatment 
decisions. Fortunately, there are a growing number of observational studies comparing 
outcomes of patients with epilepsy being treated with brand name AEDs or switched to 





events. Unfortunately, however, the results of these studies are conflicting, with some 
showing an increased risk of seizures and medical outcomes when generic AED products 
were switched with brand name products (Zachary et al., 2009), and other studies 
showing no difference in seizure control (Gagne et al., 2015). More prospective studies 
analyzing the pharmacokinetics of brand to generic substitution are needed to assess the 
true variability of generic products. It is important to ensure that every patient with 
epilepsy is receiving the best health care possible, prescribers and policy makers should 
be aware of the current state of disease management including prescribing patterns of 
generic AEDs. Our observational data suggest that brand to generic switching may be 
associated with increased rates of health services utilization which could increase 
national healthcare costs. When any medication change occurs, physicians should 
consider intense monitoring of these patients in the absence of conclusive data that 
challenge the utilization of generic substitution as there is little evidence to conclude 
discontinued use of generic AED’s (Kesselheim et al., 2010). Based on the current 
knowledge and attitudes toward generic AED formulations, we conclude that both 
patients and physicians need to advocate for education and policy that would help better 
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Objective: The purpose of this study is to examine: 1) the extent to which treatment 
switch is practiced for privately insured US patients; 2) variations in adherence to anti-
epileptic drugs (AED) by brand name and generic AED switching, and 3) medical 
outcomes based on compliance to treatment. 
Methods: A retrospective cross sectional analysis was conducted. Data were included in 
analyses if patients (1) were prescribed phenytoin or Dilantin® for seizure disorder, (2) 
experienced interchange through the use of at least one generic phenytoin prescription, 
(3) were at least 19 years of age or older at the time of medication interchange, and (4) 
had a continuous membership in their primary insurance plan for six months before and 
after medication interchange. Analyses assessed which patient classes had higher switch 
rates, medication possession ratios and medical care events.  
Results: A higher switch rate was apparent for patients who started on Dilantin® over 
patients who started treatment on phenytoin, p < 0.001, and significant differences in 
rates of compliance were apparent. Non-compliant patients were 71% more likely to 





have had an epilepsy related hospital admission, p < 0.001. The incidence rate of 
outpatient visits was 58 per 1000 person years for compliant patients; for the non-
compliant patients, the incidence rate of outpatient visits was 127 per 1000 person years, 
p < 0.001. Non-compliant patients have a significant 13% greater risk of attending the ED 
than compliant patients.  
Significance: It is important to ensure that patients, pharmacists, prescribers and policy 
decision makers are aware of the potential risks of AED switching. When medication 
change occurs physicians should consider intense monitoring of these patients. We 
conclude that both patients and physicians need to advocate for education and policy 
related to AED switching. 
Key Points: 
• Little is known about the current practice of switching from brand name to 
generic for anti-epileptic drugs 
• Higher switch rates occur for epileptic patients initially prescribed brand name 
drugs than those on generic drugs 
• Significant differences in rates of compliance occur based on whether patients are 
taking brand name or generic treatments 
• Non-compliant patients were 71% more likely to require in-patient services than 
compliant patients, and 87% more likely to have had an epilepsy related hospital 
admission 
• Non-compliant patients have a significant 13% greater risk of utilizing the ED 





• It is important to ensure that patients, prescribers, and policy decision makers are 
aware of the potential risks of AED switching 
 
Introduction 
Generic drugs have been approved for use by the Food and Drug Administration 
(FDA) since 1984 on the basis of demonstrated bioequivalence as compared to the brand 
name version. Generic drugs constitute approximately two- thirds of all prescriptions 
dispensed in the US and account for <20% of total pharmaceutical expenditure (Patel et 
al., 2011). However, concerns about the safety and bioequivalence of the generic versions 
of specific drugs are raised regularly (Kesselheim et al, 2015). Despite evidence 
supporting bioequivalence, many observational studies have shown an increase in seizure 
occurrence with the use of generic drug formulations (Papsdorf et al., 2009; Berg et al., 
2008; Yamada & Welty, 2010). These issues have not slowed the trend by medical 
insurance companies to mandate use of generic drugs over brand name drugs, and 
commercial and government insurance programs continue to prioritize the use of generics 
in most circumstances (Keenum et al., 2012). Although the use of generic medications 
can result in substantial savings for the patient, anecdotal evidence indicates that beliefs 
concerning the safety and effectiveness of generic drugs compared to brand name 
medication may persist among patient subgroups as well as among medical practitioners  
(Figueiras et al., 2010; Ngo et al., 2013). Studies investigating patient perceptions of 
generics show that although the consumer appreciates the cost savings from generics, 
some are unwilling to use them, and medication compliance could be negatively affected 





insured adults, 94% of patients agreed that generics are less expensive than brand name, 
yet only 37.6% of respondents would rather take a generic than a brand name medication 
(Kohli et.al, 2013). This effect may be especially pronounced in subgroups of patients 
characterized by factors such as culture, social status, or personal and psychological 
characteristics, as studies also show that disadvantaged consumers may be reluctant to 
use generic drugs and may distrust generic medications (Keenum et. al, 2012).	
While generic drug substitution may lead to immediate cost savings, these 
substitutions may be associated with additional expenses incurred due to increased 
adverse events, lack of adherence to therapy, and to the resulting failure of those 
therapies (Shin, 2014). Little is known about the current practice of switching from brand 
name to generic (G-switch) for anti-epileptic drugs (AED).  
         Epilepsy is one of many chronic diseases in which medication non-adherence is 
problematic. Studies estimate that between 30% and 60% of patients with epilepsy are 
non-adherent to their drug regimen, which can lead to higher seizure recurrence and 
increased medical resource utilization and costs (Davis, 2008). 	
Generic products are thought to be therapeutically interchangeable with brand 
name products and represent a cost effective alternative (Motola, 2006). A controversial 
topic is the generic substitution of AED drugs, their interchangeability and equivalency to 
the brand name version. A growing number of observational studies have compared 
patients with epilepsy being treated with brand name AEDs to those patients switched to 
generics to determine seizure control and adverse events, (Meyer, 2013) yet the results of 





The purpose of this study is to examine: 1) the extent to which G-switch is 
practiced for privately insured US patients; 2) variations in adherence to AED 
medications for patients by brand name and generic AED and switching between the two, 
and 3) medical outcomes based on compliance to treatment. We examine factors 
associated with the use the antiepileptic brand drug Dilantin® manufactured by Pfizer, 
generic phenytoin, and generic switch in 19-64 year old patients who have private 
insurance.  
Methods 
Data from the 2013 MarketScan® database was used to examine switching 
behavior and medication adherence as measured by medication possession ratios. A 
retrospective cross sectional analysis of 2013 administrative data from patients covered 
by commercial health insurance in the United States was conducted. The MarketScan® 
database was used in this setting to study the use and outcomes of therapeutics. Their size 
allows the study of infrequent events, and their representativeness of routine clinical care 
makes it possible to study real-world effectiveness and utilization patterns    
(Schneeweiss, 2005).  
For the purposes of this study, data from the MarketScan® database calendar year 
2013, containing all billing records for approximately four million covered individuals, 
were utilized. Eligible patients were identified according to International Classification of 
Diseases-9-Clinical Modification (ICD-9-CM) epilepsy diagnosis, as well as treatment by 
a medical professional. ICD-9-CM diagnosis codes 345.9, 345.0, 345.1, 345.4, 345.5 





data were included in analyses if patients 1) were prescribed phenytoin or Dilantin® for 
seizure disorder, 2) experienced some form of interchange through the use of at least one 
generic phenytoin prescription in 2010, 3) were at least 19 years of age or older at the 
time the medication interchange occurred, and 4) had a continuous membership in their 
primary insurance plan for six months before and after the medication interchange. 
Patients were excluded if they received phenytoin for neuropathy or for a pain diagnosis, 
as opposed to being prescribed the drug for a seizure diagnosis. Patients who were not 
treated for seizure disorder with a primary care physician were not considered for 
inclusion within the sample. All information from the original databases for each patient 
was carried over to the new database. Multiple hospitalizations for the same individual 
counted as separate occurrences. The raw dataset contained exposure and outcome 
variables for 6681 patients followed for one year. Summary statistics are reported as 
numbers and percentages for categorical variables, and medians and ranges for 
continuous variables. A Chi-square test was used to assess statistical significance between 
groups. Logistic regression was used to examine the relationship between  independent 
variable Dilantin and generic phenytoin and dependent variables hospital inpatient 
admission due to seizure, general hospital inpatient, outpatient visit due to seizure, and 
emergency department visit due to seizure. This analysis assessed which patient classes 
had higher switch rates. The Kruskal-Wallis nonparametric test assessed the difference in 
average medication possession ratios for 4 groups. Groups were defined as follows: 
Group 1, Start on Generic, end on Generic; Group 2, Start on Generic, switch to 
Dilantin®; Group 3, Start on Dilantin®, switch to Generic; Group 4, Start on Dilantin®, 





medication possession ratios than patients on branded Dilantin® over a one year period. 
In analyses of health outcomes, medication possession was the exposure variable and the 
analyses assessed whether patients with lower medication possession ratios were more 
likely to have medical care use indicative of seizure activity. Specifically, compliance 
with medication was defined for a patient with a ratio > 1 and non-compliant had a ratio 
< 1. Logistic regression and poisson regression were used to calculate odds ratios and 
relative risk, respectively. Compliance for this study, obtained from medication 
possession rates, was used to analyze patients on generic phenytoin or Dilantin® to 
determine if these patients had higher switch rates, medication possession ratios and 
medical care events. The medical care event outcomes identified were: total inpatient 
admissions, epilepsy related inpatient admissions, outpatient visits, and emergency 
department (ED) visits. 
All analyses were performed using R statistical software (Vienna, Austria), and 
statistical significance was determined at the 0.05 level. The SAS statistical system was 
used to gather and summarize the data.  
	
Results 
Of the 6681 patients identified, 4704 patients started treatment with phenytoin, 
and 1977 patients began their treatment with Dilantin®. Data show that 6312 of these 
patients did not switch treatments, while 369 patients had switched, resulting in a 5.5% 
switch rate in this sample overall. Within the group who started treatment on phenytoin, 
4566 patients did not switch and 138 patients switched, a switch rate of 2.9%. In the 





and 231 patients did switch, resulting in a switch rate of 11.7%. This revealed a 
significant difference in switch rates between patients who started treatment on phenytoin 
compared to those who started on Dilantin® χ2 (1, N = 507) = 202.60, p < 0.001. Patients 
who began treatment on Dilantin® were more likely to switch treatments than those who 
started their treatment with phenytoin. The difference between these rates was 
statistically significant (OR = 4.38, 95% CI [3.52-5.44], p < 0.001) as shown in Figure 1. 	
 
Figure 1: Results of logistic regression analysis on medication switch rates among 
epilepsy patients who began treatment on generic phenytoin, compared to those who 







Data from the 6681 identified patients in the MarketScan® database was used to 
compute medication possession ratios for each group of interest (Group 1: Start on 
Generic, end on Generic; Group 2: Start on Generic, switch to Dilantin®; Group 3: Start 
on Dilantin®, switch to Generic; Group 4: Start on Dilantin®, end on Dilantin®). The 
median medication possession ratio for the total sample (N = 6681) was 99.4 (IQR = 
79.65-107.80). The numbers of patients in each group were as follows; Group 1: 4566 
patients, Group 2: 138 patients, Group 3: 231 patients, Group 4: 1746 patients. Analysis 
showed significant differences in rates of compliance, as measured by possession ratios, 
among the groups (Group 1: Mdn =  98.21, IQR = 76.92-107.20, Group 2: Mdn =  98.41, 
IQR = 69.45-113.70, Group 3: Mdn =  100.30, IQR = 86.56-111.40, Group 4: Mdn =  






Figure 2. Box plot representation of compliance rates, as measured by medication 
possession ratios, for epilepsy patients in all 4 groups over one year (2013). Group 1, 
Gen/Gen includes patients who started treatment on generic phenytoin and ended on 
phenytoin (no switch from generic phenytoin); Group 2, Gen/Dil includes patients who 
started treatment on generic phenytoin and ended on Dilantin® (switched from generic 
phenytoin to Dilantin®); Group 3, Dil/Gen included patients who started treatment with 
Dilantin® and ended on generic phenytoin (switched from Dilantin® to generic 
phenytoin); Group 4, Dil/Dil includes patients who started treatment on Dilantin® and 
ended on Dilantin® (no switch from Dilantin®). The dashed horizontal line represents 





value for each group. Red boxes represent the extent of the interquartile range (1st and 3rd 
interquartile values). Outliers are represented by empty circles. 
Data regarding medical outcomes associated with compliance as measured by 
medication possession ratios was initially dichotomized by “compliance” and “non-
compliance”. This dichotomization of the data revealed that from the total sample of 
patients prescribed generic phenytoin or Dilantin®, 3216 were compliant and 3465 were 
non-compliant.  
 Data from MarketScan® also showed 642 patients requiring in-patient hospital 
admissions, 173 patients with epilepsy related admissions, 433 patients having had 
outpatient visits, and 5832 attending the emergency department (ED).  
 The mean number of ED visits was similar among compliant and non-compliant 
patients, M = 1.9 and M = 2.15, respectively. However, the range of ED visits showed 
variability, with a greater range in the number of ED visits for non-compliant (range = 
0.00-37.00) patients than for compliant patients (range = 0.00-19.00). 
 Analyses showed that 233 of the 3216 compliant patients required in-patient 
hospital admissions, compared to 409 of the 3465 non-compliant patients. These values 
result in a 7.25% admission rate for compliant patients, and an 11.80% admission rate for 
non-compliant epilepsy patients, a difference that was statistically significant, χ2 (1, N = 
442) = 39.38, p < 0.001. Non-compliant patients were 71% more likely to require in-
patient services than compliant patients, OR = 1.71, 95% CI (1.45-2.02), p < 0.001. 






Figure 3. In-patient admission rates for compliant and non-compliant epileptic patients, 
according to medication possession ratios. These data were statistically significant, p < 
0.001.  
	 Data regarding the number of epilepsy related hospital admissions for compliant 
and non-compliant epileptic patients showed that 58 compliant epileptic patients had 
epilepsy related hospital admissions during the one year period, while 115 non-compliant 
patients were admitted for epilepsy related reasons during the same year. The admission 
rates for compliant vs. non-compliant patients were 1.80% and 3.32%, respectively. This 





Figure 4, non-compliant patients were 87% more likely to have had an epilepsy related 
hospital admission than compliant patients, OR = 1.87, 95% CI (1.36-2.57), p < 0.001. 
 
Figure 4. Epilepsy related hospital admission rates for compliant and non-compliant 
patients, according to medication possession ratios. These data were statistically 
significant, p < 0.001.  
 Compliant patients experienced 188 outpatient visits overall, while non-compliant 
patients experienced 439 outpatient visits. Data also revealed that, for compliant patients, 
the incidence rate of outpatient visits was 58 per 1000 person years; for the non-





(RR = 2.17, 95% CI [1.83-2.57], p < 0.001). These differences, shown in Figure 5, were 
statistically significant.  
 
Figure 5. Incidence rates of outpatient visits for compliant and non-compliant epileptic 
patients prescribed generic phenytoin or Dilantin® in 2013  
 Compliant patients exhibited 6110 ED visits overall as a group, while non-
compliant patients attended the ED 7440 times as a group within this one year period. 
The incidence rates of ED visits for compliant and non-compliant patients were 1900 and 





This data, represented in Figure 6, also suggests that non-compliant patients have a 
significant 13% greater risk of attending the ED than do compliant patients.  
 
Figure 6. Incidence rates of emergency department visits for compliant and non-
compliant epileptic patients prescribed generic phenytoin or Dilantin® in 2013 
 
Continuous variable data for medication possession revealed that a 1% positive 
change in compliance resulted in a statistically significant 1% decrease in the number of 
in-patient hospital admissions, OR = 0.99, 95% CI (0.98-0.99), p < 0.001. Additionally, a 





hospitalization which was also statistically significant, OR = 0.88, 95% CI (0.86-0.90), p 
< 0.001. Similarly, a 1% positive change in compliance resulted in a 2% decrease in 
epilepsy related hospital admissions, OR = 0.98, 95% CI (0.98-0.98), p < 0.001. A 10% 
positive change in compliance was related to a 16% decrease in epilepsy related 
admissions, OR = 0.84, 95% CI (0.81-0.88), p < 0.001. Analyses of continuous outpatient 
visit data indicated that a 1% positive change in compliance resulted in a statistically 
significant 1% decrease in the number of outpatient visits (OR = 0.99, 95% CI [0.98-
0.99], p < 0.001), while a 10% positive change in compliance resulted in a 13% decrease 
in outpatient visits which was also statistically significant (OR = 0.87, 95% CI [0.85-
0.89], p < 0.001).  Data regarding the number of ED visits in epilepsy patients revealed 
that a 1% positive change in compliance corresponded to a less than 1% decrease in the 
number of ED visits, yet this change was statistically significant, OR = 1.00, 95% CI 
(1.00-1.00), p < 0.001. A 10% positive change in compliance resulted in a statistically 
significant 3% decrease in ED visits, OR = 0.97, 95% CI (0.96-0.97), p < 0.001. These 













This study was designed to provide an assessment of brand name Dilantin® and 
generic phenytoin, comparing switch rates, compliance, and seizure related health 
outcomes, as there is growing concern about the efficacy and safety of generic AED’s  
(Haskins et. al, 2005). Health policy and managed care practices often focus on cost 
containment and may encourage the use of generics because they are less expensive than 
their branded counterparts. What may be greatly underestimated are the additional 
unexpected costs associated with switching drugs and drug taking compliance, which can 
cause both an increase in adverse events and increased medical use, such as 
hospitalization and emergency room visits. 
Results from this large managed care database demonstrated that patients treated 
with phenytoin had a lower switch rate than those patients who started treatment on 
Dilantin®.  These initial results support existing evidence suggesting that patients who 
begin treatment on a branded AED (i.e. Dilantin®) are more likely to switch treatment to 
a generic. However, an unexpected finding in our study suggests that those who start 
treatment on phenytoin and switch to Dilantin® are the least compliant compared to other 
groups in our analyses. Study investigators initially hypothesized that switches to brand 
name Dilantin® would prove better compliance outcomes, yet this switch showed the 
opposite effect, a finding which is inconsistent with previous studies conducted in this 
area. The greatest rates of compliance were evident in the Dilantin® treated patients who 
experienced no switch, and therefore remained on the brand name drug during our one 
year review period. A recent study by Gagne and colleagues (2015) showed differing 





better for generic AED’s than their branded versions, and that better medication 
adherence was associated with better patient outcomes. Additionally, these authors noted 
that generics were more effective than their brand name counterparts, further alluding to 
the need for additional research in this area. 
 Additionally, the present study confirmed a relationship between brand or generic 
AED compliance and inpatient hospital use, outpatient services, and ED visits. Non-
compliant patients were significantly more likely to require in-patient services than 
compliant patients, had greater than twice the risk of requiring outpatient services than 
compliant patients, and were at a significantly greater risk for attending the ED than 
compliant patients. These results are in line with previous research (Zachry et.al, 2009) 
which provide further evidence that AED substitution may increase use of health care 
services and strengthen the association between switching and adverse outcomes. 
Furthermore, a systematic review of the current evidence on generic substitution of AEDs  
(Yamada et al., 2011) including both retrospective and prospective controlled study 
analyses of generic substitution of AEDs, found that the majority of retrospective studies 
had indicated that generic AED substitution resulted in higher use of medical services in 
patients with epilepsy. Our study, as well as those noted here, suggest that switching to 
generic may be associated with increased rates of health services utilization and lower 
medication possession ratios. It is important to ensure that patients, pharmacists, 
prescribers and policy decision makers are aware of the potential risks. 
Our analyses support existing concerns and challenges associated with AED 
switching, for both patients and health care providers. Until formal guidelines are 





experience the negative effects of AED switching. It is clear from our literature review 
that many physicians are concerned about the efficacy and safety associated with 
unhampered substitution of generic AEDs, but may inaccurately underestimate how often 
generic substitution occurs (Wilner, 2002). Policies that include mandatory substitution 
or substitution without informed consent to both patient and provider are clearly 
passionate topics and warrant further discussion (Maliepaard et al., 2009). Strong 
recommendations regarding generic substitution from The Epilepsy Society and The 
American Academy of Neurology as well as other advocacy and medical authorities 
detail anecdotal evidence as well as clinical concerns regarding generic substitution. 
Several states have issued laws regarding generic substitution, while other states are 
considering implementation of similar legislation (Meyer et al., 2013). Supplementing the 
existing body of knowledge, The Agency for Healthcare Research and Quality conducted 
a comparative effectiveness review in December 2011, which evaluated the effectiveness 
and safety of AEDs in patients with epilepsy. The review states that patients who initiate 
treatment with and AED have no substantive differences in benefits or harms associated 
with the use of generics versus brand name products (Talati et al., 2011). The review also 
acknowledges that switching from a brand name AED to a generic AED may increase 
health care utilization, but recognizes that “this is based on controlled observational study 
data, which has inherent limitations substantially reducing the strength of evidence” 
(Talati et al., 2011). These groups aim to scrutinize the need for continued robust studies 
to evaluate generic AED substitution, and to directly examine the clinical effects of brand 





The results of this study provide additional substance and contributory evidence 
to the area of research regarding epilepsy treatment, switching, and associated medical 
events. Our study, however, does have its limitations. The first major limitation was the 
use of observational data from a managed care database, and not utilizing a randomized 
controlled trial design, which might have included additional patient data such as disease 
characteristics, seizure frequency, disease duration or patients identified on multiple 
AED’s.  Our research falls short of specifically identifying whether generic AED’s 
directly affect the risk of breakthrough seizures, however does include important results 
regarding compliance and medical care use.  
This study reinforces evidence showing that when an AED formulation switch 
occurs, additional patient monitoring is necessary and patients should be considered 
individually regarding the appropriateness for changes in treatment formulation. There 
remain important considerations when substituting AED’s as compared to other chronic 
or acute medications that need to be underscored. It is clear that further clinical studies 
are needed to determine outcomes or possible pitfalls of generic substitution to guide 
treatment decisions. Fortunately, there are a growing number of observational studies 
comparing outcomes of patients with epilepsy being treated with brand name AEDs or 
switched to generic to determine if there are differences in seizure control or seizure-
related adverse events. Unfortunately, however, the results of these studies are 
conflicting, with some showing an increased risk of seizures and negative medical 
outcomes when generic AED products were switched with brand name products (Zachry 
et al., 2009) and other studies showing no difference in seizure control (Gagne et al., 





substitution are needed to assess the true variability of generic product use and switch. It 
is important to ensure that every patient with epilepsy is receiving the best health care 
possible, and thus prescribers and policy makers should be aware of the current state of 
disease management including prescribing patterns of generic AEDs. When any 
medication change occurs, physicians should consider intense monitoring of these 
patients in the absence of conclusive data that support or challenge the utilization of 
generic substitution (Kesselheim et al., 2015). Based on the current knowledge and 
attitudes toward generic AED formulations, we conclude that both patients and 
physicians need to advocate for education and policy that would help better inform and 
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